Table 5.
CSMT, TMV and VA at baseline, 3.5 and 12 months by Baseline Number of Thickened Subfields (N = 317 eyes*)
| Baseline Number of Thickened Subfields |
r | |||||
|---|---|---|---|---|---|---|
| N | 0–2 N (%) | 3–4 N (%) | 5–6 N (%) | 7–9 N (%) | ||
| CSMT Baseline | 0.64 | |||||
| <300 microns | 155 | 74 (81%) | 42 (62%) | 23 (36%) | 16 (17%) | |
| 300-<400 microns | 82 | 17 (19%) | 17 (25%) | 26 (41%) | 22 (23%) | |
| 400-<500 microns | 47 | 0 | 9 (13%) | 14 (22%) | 24 (26%) | |
| ≥500 microns | 33 | 0 | 0 | 1 (2%) | 32 (34%) | |
| Total | 317 | 91 (100%) | 68 (100%) | 64 (100%) | 94 (100%) | |
| median (25th, 75th) | 317 | 254 (228, 278) | 284 (257, 335) | 324 (278, 394) | 438 (347, 524) | |
| CSMT 3.5 mo. Change | 0.26 | |||||
| median (25th, 75th) | 297 | −3 (−24,+17) | −2 (−36,+22) | −4 (−68,+16) | −50 (−144,+14) | |
| CSMT 12 mo. Change | 0.35 | |||||
| median (25th, 75th) | 272 | −15 (−39,+7) | −13 (−57,+18) | −45 (−94,+18) | −119 (−217, −11) | |
| TMV Baseline | 0.77 | |||||
| <7 mm3 | 16 | 16 (19%) | 0 | 0 | 0 | |
| 7-<8 mm3 | 94 | 62 (74%) | 29 (59%) | 3 (6%) | 0 | |
| 8-<9 mm3 | 74 | 6 (7%) | 19 (39%) | 40 (75%) | 9 (13%) | |
| ≥9 mm3 | 73 | 0 | 1 (2%) | 10 (19%) | 62 (87%) | |
| Total | 257 | 84 (100%) | 49 (100%) | 53 (100%) | 71 (100%) | |
| median (25th, 75th) | 257 | 7.4 (7.1, 7.8) | 7.9 (7.6, 8.2) | 8.6 (8.3, 8.8) | 9.6 (9.2, 10.7) | |
| TMV 3.5 mo. Change | 0.11 | |||||
| median (25th, 75th) | 205 | 0 (−0.3,+0.1) | −0.2 (−0.7, −0.1) | −0.3 (−0.6,0.0) | −0.4 (−1.2,+0.2) | |
| TMV 12 mo. Change | 0.34 | |||||
| median (25th, 75th) | 198 | −0.2 (−0.5,+0.1) | −0.4 (−1.1, −0.2) | −0.6 (−1.0, −0.1) | −1.1 (−2.4, −0.6) | |
| VA Baseline | 0.38 | |||||
| >=84 | 74 | 35 (38%) | 16 (24%) | 15 (23%) | 8 (9%) | |
| 69–83 letters | 164 | 49 (54%) | 35 (51%) | 33 (52%) | 47 (50%) | |
| 19–68 letters | 79 | 7 (8%) | 17 (25%) | 16 (25%) | 39 (41%) | |
| Total | 317 | 91 (100%) | 68 (100%) | 64 (100%) | 94 (100%) | |
| median (25th, 75th) | 317 | 81 (75, 86) | 78 (69, 83) | 76 (69, 83) | 71 (64, 76) | |
| VA 3.5 Month Change | 0.08 | |||||
| median (25th, 75th) | 301 | 0 (−4,+4) | +1 (−4,+4) | +2 (−3,+6) | −2 (−8,+6) | |
| VA 12 Month Change | <0.01 | |||||
| median (25th, 75th) | 278 | −1 (−5,+3) | −1 (−4,+4) | +2 (−5,+6) | +1 (−6,+7) | |
| # Additional Laser Treatments Through12 Monthsa | ||||||
| 0 | 131 | 45 (49%) | 32 (47%) | 25 (39%) | 29 (31%) | |
| 1 | 110 | 33 (36%) | 25 (37%) | 20 (31%) | 32 (34%) | |
| 2 | 76 | 13 (14%) | 11 (16%) | 19 (30%) | 33 (35%) | |
*
Excludes 6 eyes with all nine OCT zones ungradable at baseline.
a
laser treatment performed after the initial treatment